Logo

GSK Signs an Exclusive License Agreement with Surface Oncology to Develop and Commercialize SRF813

Share this

GSK Signs an Exclusive License Agreement with Surface Oncology to Develop and Commercialize SRF813

Shots:

  • Surface Oncology to receive ~$85 M upfront and ~$730 M as milestones along with royalties on net sales of SRF813
  • GSK to get an exclusive right to develop and commercialize Surface Oncology’s preclinical program- SRF813
  • SRF813 is an IgG1 Ab targeting PVRIG (also k/a CD112)- currently in IND-enabling studies with anticipated IND submission in 2021

 ­ Ref: Globe Newswire | Image: GSK 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions